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The excision repair cross-complementing group 1 (ERCC1) gene performs a critical incision step in DNA repair and is reported to
becorrelatedwithcarcinogenesisandresistancetodrugorionizingradiationtherapy.WereviewedthecorrelationbetweenERCC1
and bladder cancer. In carcinogenesis, several reports discussed the relation between ERCC1 single nucleotide polymorphisms
and carcinogenesis in bladder cancer only in case-control studies. Regarding the relation between ERCC1 and resistance to
chemoradiotherapy, in vitro and clinical studies indicate that ERCC1 might be related to resistance to radiation therapy rather
than cisplatin therapy. It is controversial whether ERCC1 predicts prognosis of bladder cancer treated with cisplatin-based
chemotherapy. Tyrosine kinase receptors or endothelial-mesenchymal transitionare reported to regulate theexpression of ERCC1,
and further study is needed to clarify the mechanism of ERCC1 expression and resistance to chemoradiotherapy in vitro and to
discover novel therapies for advanced and metastatic bladder cancer.
1.Introduction
Bladder cancer is the fourth most common cancer in men
in the United States [1, 2] .B l a d d e rc a n c e ri sm o r ep r e v a l e n t
in men than women, with men accounting for around 80%
of cases. Up to one-half of bladder cancer cases in men and
one-third in women are caused by cigarette smoking [3, 4],
and another important risk factor is occupational exposure
to various chemical carcinogens [5]. A common property
of these exposures is the presence of carcinogens that can
induce DNA damage in the bladder epithelium. Genotoxic
compounds derived from the metabolism of chemical car-
cinogenscancontributetotheaccumulationofseveralforms
of DNA damage, such as bulky adducts, single-strand breaks
(SSBs) and double-strand breaks (DSBs), abasic sites, and
modiﬁed bases. DNA repair mechanisms exist to prevent
detrimental consequences of these types of DNA damage.
Speciﬁcally, base damage, abasic sites, and SSBs are repaired
through the base excision repair (BER) pathway, whereas
DSBs are repaired by either nonhomologous end joining
or the homologous recombination repair (HRR) pathways.
Bulky adducts are generally repaired by the nucleotide
excision repair (NER) pathway. An overall association was
reported between genetic variation in the NER pathway and
bladdercancerrisk,suggestingthepresenceofgene-geneand
gene-smoking interactions [6].
On the other hand, systemic radiotherapy and chemo-
therapy including cisplatin are used for locally advanced
or metastatic bladder cancer, but their response rates are
approximately 50%–60% [7, 8]. DNA-damaging chemother-
apeutic drugs and ionizing radiation (IR) induce a variety of
DNA lesions in cancer cells as well as in normal cells. The
mechanisms of cisplatin and radiation resistance have been
studied in various bladder cancer cell lines, and it has been
shown that various DNA repair genes play important roles
in resistance to various therapies [9, 10].
The excision repair cross-complementing group 1
(ERCC1) gene is located on chromosome 19q13.2-q13.3
[11]. ERCC1 performs a critical incision step in NER
and is also involved in the repair of DNA interstrand
crosslinks and some DSBs [12–14]. In clinical studies, the
expressionofERCC1inﬂuencedtheprognosisofthepatients
treated with cisplatin-based chemotherapy and chemora-
diotherapy (CRT) in various cancers such as lung cancer2 Advances in Urology
[15, 16]. Recently, several reports addressed the relation
between ERCC1 expression and prognosis for cisplatin-
based chemotherapy for bladder cancer [17–19], and we
also reported that ERCC1 might become a good factor for
predicting the eﬃcacy of CRT for muscle-invasive bladder
cancer (MIBC) [20]. In accordance with these previous
reports, we review the role of ERCC1 in bladder cancer from
carcinogenesis to therapeutic resistance.
2. ERCC1andCarcinogenesisofBladderCancer
Chemical carcinogens, such as tobacco smoke and aromatic
amines, can undergo metabolic activation and detoxiﬁcation
in the liver, and polymorphisms in the relevant genes
have been shown to be associated with bladder cancer risk
[21–23]. Additionally, DNA repair enzymes are required
to repair the DNA damage associated with exposure to
carcinogens. This suggests that common genetic variation
in DNA repair genes might inﬂuence the risk of bladder
cancer, and several reports examined the relation between
single nucleotide polymorphisms (SNPs) in DNA repair
genes and carcinogenesis. In case-control studies, several
reports discussed the relation between ERCC1 SNPs and
carcinogenesis in bladder cancer [6, 24–26]. Matullo et al.
reported that the ERCC1-19007C variant allele (CC+CT
versus TT: odds ratio (OR), 0.62; 95% conﬁdence interval
(CI), 0.41–0.95) decreased the risk of bladder cancer, which
was consistent across smoking groups, although its SNP
did not aﬀect carcinogenesis in nonsmoking groups. They
mentioned that the ERCC1-19007 C>T polymorphism leads
to a silent Asn118Asn change, but other polymorphisms
and a combination of SNPs in the ERCC1 gene could be
more important than single SNPs [24]. Garc´ ıa-Closas et al.
examined the SNPs in the NER pathway and bladder cancer
risk. Compared with homozygous wild-type individuals,
those carrying genotypes with variant alleles for ERCC1
IVS5+33A>C had a signiﬁcant increase in risk (OR, 1.2; 95%
CI, 1.0–1.5; P(trend) = 0.04), and the association of ERCC1
with bladder cancer risk seemed to be stronger for cigarette
smokers than for never-smokers [6]. Recently, Ricceri et al.
reported that a single SNP analysis showed a protective eﬀect
of the rare alleles of 3 ERCC1 SNPs: rs967591 (OR, 0.66; CI
95%, 0.46–0.95), rs735482 (OR, 0.62; CI 95%, 0.42–0.90),
and rs2336219 (OR, 0.63; CI 95%, 0.43–0.93). Moreover,
haplotype analysis revealed that cases of bladder cancer had
a statistically signiﬁcant excess of ERCC1-GAT haplotypes
[26]. These reports were only case-control studies, and
ERCC1 was not included in other meta-analyses [27]. From
now forward, a detailed characterization of ERCC1 variation
is warranted, and it is necessary to pool comparable data
andidentifymultiplesusceptibilityvariantsthatcouldjointly
aﬀect risk.
3.The Role of ERCC1inCisplatinand
IR Resistance in Bladder Cancer In Vitro
ERCC1 is a crucial gene in the NER pathway. Cisplatin-
DNA adducts are removed via the NER pathway, and an
association of diﬀerent cancer cell lines with resistance to
platinum compounds has been suggested [28, 29]. Welsh
et al. reported that ERCC1 expression in bladder cancer
cell lines was higher than that in testis tumor cell lines,
and it led to less sensitivity to cisplatin-based chemotherapy
in bladder cancer than that in testicular cancer [30]. We
examined ERCC1 expression in four bladder cancer cell lines
including two cisplatin-resistant cell lines. The cells most
resistant to cisplatin had the highest ERCC1 expression,
but sensitivity to cisplatin was not signiﬁcantly recovered
by ERCC1 knocked down by siRNA [20]. Usanova et al.
reported that downregulation of ERCC1-XPF slightly but
signiﬁcantly increased the sensitivity to cisplatin in one
bladder cancer cell line [10]. These reports indicate that
ERCC1 might play a slight role in the resistance to cisplatin
therapy in bladder cancer.
InregardtotheassociationbetweenERCC1andsensitiv-
ity to IR, Ahmad et al. reported that ERCC1-XPF is required
for DNA DSB repair, and ERCC1-deﬁcient cells are sensitive
to IR exposure [13]. Liu et al. reported that methylation
of the ERCC1 promoter correlates with radiosensitivity in
gliomacelllines[31].Wereportedthatoffourbladdercancer
cell lines, the cell line with the highest ERCC1 expression
was also the most resistant to IR exposure. Moreover, the
sensitivity to IR exposure recovered signiﬁcantly in the two
cells lines in which ERCC1 was knocked down [20]. To our
knowledge, there are no other reports addressing the relation
between ERCC1 expression and IR resistance in bladder
cancer. DSBs are the most lethal form of IR-induced DNA
damage, and recent studies have observed a close correlation
betweenthenumberofphospho-H2A.Xfociandthenumber
ofexpectedDSBsafterirradiation.Inourstudy,twocelllines
in which ERCC1 was knocked down recovered more slowly
in terms of the number of phospho-H2A.X foci than did the
control,suggestingcontinuedaccumulationorpersistenceof
DSBs and an increase the sensitivity to IR exposure. Based
on our in vitro data, ERCC1 might play greater roles in
IR resistance in some bladder cancers; however, we did not
show a direct correlation between ERCC1 and IR resistance
in bladder cancer cells. Yacoub et al. reported that EGFR-
ERK-signaling-induced IR-regulated DNA repair proteins
XRCC1 and ERCC1 in prostate carcinoma cells [32]. Ko et
al. reported that the level of ERK1/2 correlated with DNA
repair genes, such as ERCC1 and Rad51 [33]. In clinical
studies, EGFR played the key role in drug and radiation
resistance [34, 35], and further study is needed to examine
the diﬀerence between cisplatin and IR resistance associated
with ERCC1, as well as other molecular pathways regulating
ERCC1.
4. ERCC1 and the Efﬁcacy of CRT for MIBC
The gold standard treatment for MIBC is radical cystectomy
and urinary diversion. Concurrent CRT using cisplatin or
other agents is an alternative therapy that preserves bladder
function [7, 36–40]. Because the complete response (CR)
rate of CRT for MIBC is 60–70%, a simple procedure is
needed to select patients with MIBC who can be expectedAdvances in Urology 3
to have a good response to CRT so that they will not miss the
chance to be cured by immediate cystectomy.
In terms of a predictor of the clinical response of CRT
for MIBC by immunohistochemical study, Chakravarti et
al. reported that in a multivariate analysis, only Her-2
expression was signiﬁcantly associated with a reduced rate of
CR after CRT [34]. R¨ odel et al. reported that the apoptotic
index and Ki-67 expression, but not p53 or bcl-2 expression,
were signiﬁcantly related to an initial CR after CRT [41].
Matsumoto et al. suggested that only the Bax/Bcl-2 ratio
was associated with the CR rate, although Bax and Bcl-2
individually were not signiﬁcantly associated with the CR
rate [42]. In terms of DNA repair genes, Sakano et al. studied
NER, BER, and HRR SNPs in 78 patients, looking at the
eﬀect on response and prognosis following platinum-based
CRT. They found the recurrencerate to be signiﬁcantly lower
in patients with a greater number of total variant alleles
in all DNA repair genes and in NER genes, not including
ERCC1 (P = 0.03), and the total number of variant alleles
were signiﬁcantly associated with improved cancer-speciﬁc
survival in a univariate analysis. These ﬁndings suggested
that NER genes might play an important role in the outcome
of CRT for MIBC [43].
In terms of our previously mentioned in vitro data, we
examined ERCC1 expression level by immunohistochem-
istry in all 22 patients who underwent CRT for MIBC. All
patients were treated with aggressive transurethral resection
of bladder tumor before CRT in Osaka University Graduate
school of Medicine and its aﬃliated hospital. With standard
fractionation (2Gy/fraction), the median total radiation
dose is 50Gy (40–66). Moreover, concurrent platinum
chemotherapy with cisplatin (n = 13) and nedaplatin (n =
9)wasintravenouslyadministeredwithintheﬁrstandfourth
week and administered doses were ranged from 100mg to
280mg. Six of the 8 ERCC1-positive patients showed a non-
CR after CRT, whereas 12 of the 14 ERCC1-negative patients
showed a CR. The eﬃcacy of CRT as determined by ERCC1
expression level had a sensitivity of 75% and speciﬁcity of
85.7% (P = 0.008). Finally, we examined the correlation
between ERCC1 immunoreactivity and 5-year survival in
the MIBC patients undergoing CRT. Overall 5-year survival
was 31.2% in the ERRC1-positive and 69.2% in the ERRC1-
negative patients (P = 0.088). Although the sample size of
our study was small, our in vitro data showed that lack of
ERCC1 expression may predict the eﬃcacy of CRT for MIBC
[20].
In breast cancer, the nuclear expression of Her-2 modu-
lated the interstrand crosslink repair of speciﬁc DNA lesions
producedbychemotherapy[44].Althoughwedidnotexam-
ine Her-2 expression in our previous study, further study is
needed to examine the relation between Her-2 expression
and DNA repair genes, such as ERCC1, in bladder cancer.
One personalized randomized phase I/II study (RTOG-
0524) was conducted using Her-2 immunohistochemistry
in bladder cancer treated with radiotherapy combined with
chemotherapy. The results of this clinical study warrant
further investigation about the relation between them.
Moreover, Fleischmann et al. recently reported that Her-2
expression in lymph node metastasis was higher than that
in primary bladder tumors [45]. It will be important to
assess novel CRTs targeting the Her-2/DNA repair pathway
in advanced bladder cancer with metastasis.
5. ERCC1 andthe Efﬁcacy of
Cisplatin-BasedChemotherapy
In a clinical study using immunohistochemistry, Olaussen
et al. reported that patients with ERCC1-negative nonsmall
cell lung cancer appeared to beneﬁt from adjuvant cisplatin-
based chemotherapy, whereas patients with ERCC1-positive
tumors did not [15]. In advanced bladder cancer, Bell-
munt et al. were the ﬁrst to report that patients with
a high mRNA level of ERCC1 had poorer prognosis for
cisplatin-based chemotherapy than did patients with a low
mRNA level of ERCC1 [17]. However, the authors did
not make a general statement concerning the inﬂuence
of ERCC1 expression on the outcome of other treatment
regimens including radiotherapy. In adjuvant cisplatin-
based chemotherapy for MIBC, Hoﬀmann et al. reported
that high mRNA levels of ERCC1 and MDR1 predicted
inferior progression-free survival [18] .V a r i o u sr e g i m e n so f
cisplatin-based chemotherapy were used in these previous
reports.ERCC1expressionwasnotdiﬀerentbetweenthetwo
platinum-based treatment arms (CMV versus M-VAC), and
there was no signiﬁcant relation between ERCC1 expression
and progression-free survival in either therapeutic regimen
(P = 0.21,P = 0.07)[18].Matsumuraetal.reportedthatthe
expressionofnotERCC1buthumanequilibrativenucleoside
transporter 1 (hENT1) could predict prognosis in patients
treated with gemcitabine and cisplatin (GC) therapy in an
immunohistochemical study [46]. As the major molecular
component of nucleoside transporter proteins, hENT1 has
been shown to predict beneﬁt in patients undergoing gem-
citabine chemotherapy for several solid malignancies [47,
48]. Matsumura et al. reported that only hENT1 expression
(P = 0.004) and not ERCC1 expression (P = 0.182) was
associatedwiththeprognosisofoverallsurvivalbymultivari-
ate analysis. Kim et al. reported that immunohistochemical
expression of ERCC1 could predict only progression-free
survival and not overall survival for advanced bladder cancer
treated with GC and M-VAC therapies. They indicated that
ERCC1 negativity was a statistically signiﬁcant independent
prognostic marker for progression-free survival (OR, 1.62;
95% CI, 1.03–2.54; P = 0.003) [19]. The role of ERCC1
as it relates to resistance to cisplatin was controversial in
clinical studies of bladder cancer. Recently, we examined
the prognosis of cisplatin-based neoadjuvant chemotherapy
in 58 bladder cancer patients treated with M-VAC and GC
therapy using the results of an immunohistochemical study
of ERCC1. The expression of ERCC1 could not predict CR
or the prognosis for either disease-free or overall survival
(data not shown). Hsu et al. reported that Snail, one of
the endothelial-mesenchymal transition (EMT) markers,
regulated the expression of ERCC1, and coexpression of
Snail and ERCC1 predicted the poor prognosis of cisplatin-
based chemotherapy for head and neck cancer [49]. EMT
is reported to play an important role in progression and4 Advances in Urology
resistance to radiotherapy and chemotherapy in bladder
cancer and other malignancies [35, 50–53]. We previously
examined Snail expression and found that it correlated with
ERCC1 expression (P = 0.001). Moreover, coexpression of
ERCC1andSnailwerealsofoundtobetheprognosticfactors
to predict poorer disease-free and overall survival by both
univariate and multivariate analysis in all cases examined. In
this study, coexpression of ERCC1 and Snail were prognostic
factorsonly in the patients undergoing M-VAC therapy (data
not shown). In these above studies, the ERK1/2-Snail/Slug
pathway including tyrosine kinase receptors such as Her2
or EGFR might regulate the expression of ERCC1, and
further in vitro and clinical study is needed to clarify the
relationbetweenERCC1andcisplatinresistance.Inaddition,
prospectiverandomizedtrialsoftherapybasedonexpression
levels of ERCC1, such as that performed in lung cancer, are
needed [54].
6. Conclusion
We reviewed the role of ERCC1 in bladder cancer from
carcinogenesis to therapeutic resistance. In bladder cancer,
ERCC1 might become an important factor to predict
cisplatin resistance as in other malignancies, and our in vitro
results suggested that in some bladder cancer cells, ERCC1
expression correlates with resistance to IR but not with
resistance to cisplatin. Moreover, lack of ERCC1 expression
correlated well with the eﬃcacy of CRT and especially with
that of IR. Tyrosine kinase receptors such as EGFR and
Her2 might regulate the expression of ERCC1, and EMT
is closely correlated with the expression of ERCC1. Further
study is needed to clarify the mechanism of the relation
between ERCC1 and resistance to cisplatin and IR in vitro
and to discover novel CRTs for the treatment of advanced
and metastatic bladder cancers.
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